CA2616712C - Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique - Google Patents

Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique Download PDF

Info

Publication number
CA2616712C
CA2616712C CA2616712A CA2616712A CA2616712C CA 2616712 C CA2616712 C CA 2616712C CA 2616712 A CA2616712 A CA 2616712A CA 2616712 A CA2616712 A CA 2616712A CA 2616712 C CA2616712 C CA 2616712C
Authority
CA
Canada
Prior art keywords
cell
ephrin
marker
ephb
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2616712A
Other languages
English (en)
French (fr)
Other versions
CA2616712A1 (fr
Inventor
Philippe Foubert
Jean-Sebastien Silvestre
Sophie Le Ricousse-Roussanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Original Assignee
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Diderot Paris 7, IVS Institut des Vaisseaux et du Sang filed Critical Universite Paris Diderot Paris 7
Publication of CA2616712A1 publication Critical patent/CA2616712A1/fr
Application granted granted Critical
Publication of CA2616712C publication Critical patent/CA2616712C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2616712A 2005-07-27 2006-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique Expired - Fee Related CA2616712C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0508029A FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
FR0508029 2005-07-27
PCT/FR2006/001837 WO2007012764A2 (fr) 2005-07-27 2006-07-27 Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique

Publications (2)

Publication Number Publication Date
CA2616712A1 CA2616712A1 (fr) 2007-02-01
CA2616712C true CA2616712C (fr) 2015-11-17

Family

ID=36353668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2616712A Expired - Fee Related CA2616712C (fr) 2005-07-27 2006-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique

Country Status (11)

Country Link
US (1) US8338169B2 (https=)
EP (1) EP1913130B1 (https=)
JP (4) JP5755829B2 (https=)
CN (1) CN101273123B (https=)
AU (1) AU2006273928B2 (https=)
CA (1) CA2616712C (https=)
DK (1) DK1913130T3 (https=)
ES (1) ES2565675T3 (https=)
FR (1) FR2889200B1 (https=)
IL (1) IL188938A (https=)
WO (1) WO2007012764A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
AU2008223817A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
JP2002531384A (ja) 1998-11-20 2002-09-24 マウント サイナイ ホスピタル ＢクラスｅｐｈｒｉｎとＰＤＺ領域との相互作用を変調するペプチド
US20040018199A1 (en) 1999-10-15 2004-01-29 Raj Bandaru Compositions and methods of use for an ephrin receptor
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
US6919313B2 (en) 2001-03-30 2005-07-19 President & Fellows Of Harvard College Protein waving a PDZ and a RGS domain
US20050049194A1 (en) 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
CA2518912A1 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
CA2616712A1 (fr) 2007-02-01
FR2889200A1 (fr) 2007-02-02
IL188938A (en) 2014-09-30
JP2015061536A (ja) 2015-04-02
ES2565675T3 (es) 2016-04-06
DK1913130T3 (en) 2016-03-29
JP2017169590A (ja) 2017-09-28
CN101273123B (zh) 2013-06-26
EP1913130B1 (fr) 2015-12-23
JP5755829B2 (ja) 2015-07-29
IL188938A0 (en) 2008-04-13
WO2007012764A2 (fr) 2007-02-01
US8338169B2 (en) 2012-12-25
WO2007012764A3 (fr) 2007-05-31
JP2016127863A (ja) 2016-07-14
CN101273123A (zh) 2008-09-24
JP6235639B2 (ja) 2017-11-22
AU2006273928B2 (en) 2012-02-16
EP1913130A2 (fr) 2008-04-23
AU2006273928A1 (en) 2007-02-01
JP5981525B2 (ja) 2016-08-31
US20090123431A1 (en) 2009-05-14
FR2889200B1 (fr) 2008-01-04
JP2009505638A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
Deng et al. Biotin–avidin system-based delivery enhances the therapeutic performance of MSC-derived exosomes
Masgutov et al. Allogenic adipose derived stem cells transplantation improved sciatic nerve regeneration in rats: autologous nerve graft model
JPH08503198A (ja) Ｏｐ−３誘導形態形成
CA2616712C (fr) Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
EP3759153A1 (fr) Hydrogel pour stimuler la neurotisation, l'osteogenese et l'angiogenese
Yang et al. Engineered extracellular vesicles from antler blastema progenitor cells: A therapeutic choice for spinal cord injury
WO2005009366A2 (en) Restoring vascular function
JP2013518588A (ja) 間充織幹細胞の分離及び培養方法
CA2297303C (fr) Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux
EP2101795A2 (fr) Préparations cellulaires pour une utilisation comme agent stimulant la revascularisation
Andersson et al. Extracellular vesicles for nerve regeneration
CA2184200A1 (fr) Virus recombinants, preparation et utlisation en therapie genique
CA2793985C (fr) Compositions proangiogeniques, leur procede de preparation et leurs utilisations
WO2025100511A1 (ja) 融合ペプチド
Chao Ablation of FAP+ stromal cells impairs endogenous revascularization during hind limb ischemia
FR2910003A1 (fr) Nouveaux peptides et polypeptides a stabilite amelioree utiles dans la regeneration du systeme nerveux
Dai Matsuse et al. Human Umbilical CordYDerived Mesenchymal Stromal Cells Differentiate Into Functional Schwann Cells That Sustain Peripheral Nerve Regeneration
YAHIA DIFFERENTIAL RESPONSE OF PATELLAR TENDON, ANTERIOR AND POSTERIOR CRUCIATE LIGAMENTS FIBROBLASTS SUBMITTED TO

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210727